Get the Stockscreener App
205.07
3.51%
6.96
Pre-market:
206.32
1.25
+0.61%
Icon Plc stock is traded at $205.07, with a volume of 938.26K.
It is up +3.51% in the last 24 hours and down -1.18% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$198.11
Open:
$198.71
24h Volume:
938.26K
Relative Volume:
0.70
Market Cap:
$16.93B
Revenue:
$8.31B
Net Income/Loss:
$747.89M
P/E Ratio:
22.86
EPS:
8.97
Net Cash Flow:
$1.23B
1W Performance:
+2.41%
1M Performance:
-1.18%
6M Performance:
-37.80%
1Y Performance:
-21.00%
1-Day Range:
$197.83
$205.31
1-Week Range:
$196.50
$205.31
52-Week Range:
$183.38
$347.72
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
205.07 | 16.93B | 8.31B | 747.89M | 1.23B | 8.97 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Icon (ICLR) 3-Year EPS without NRI Growth Rate : 8.70% (As of Sep. 2024) - GuruFocus.com
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates - MSN
Icon sees FY25 adjusted EPS $13.00-$15.00, consensus $14.93 - Yahoo Finance
Icon PLC (ICLR) Stock Price Down 6.6% on Jan 14 - GuruFocus.com
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty - Benzinga
ICON plc stock retains Overweight rating amid conservative growth forecasts - Investing.com India
ICON plc stock retains Overweight rating amid conservative growth forecasts By Investing.com - Investing.com South Africa
Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies - GlobeNewswire Inc.
ICON Issues Financial Guidance for Full Year 2025 - sharewise
ICON plc Announces 2025 Financial Guidance Amid Market Challenges - TipRanks
Decentralized Clinical Trials Market Recent Growth: Market - openPR
ICON Public (NASDAQ:ICLR) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
ICON Survey: 97% Use Biomarkers in Neurodegenerative Trials, But Innovation Gaps Persist - StockTitan
RBC Capital Initiates Coverage of ICON Public Limited (ICLR) with Outperform Recommendation - MSN
ICON's SWOT analysis: CRO giant faces headwinds amid long-term growth potential - Investing.com India
ICON plc draws bullish views at RBC on attractive valuation - MSN
Icon PLC (ICLR) Stock Price Up 4.66% on Jan 7 - GuruFocus.com
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
ICON plc to Present at the J.P. Morgan Healthcare Conference - TipRanks
Why Icon Plc Shares Face Rocky Times Ahead - TipRanks
ICON Properties Plc (ICON.mw) Q42024 Interim Report - AfricanFinancials
ICON Clinches TIME Magazine's Top CRO Ranking, Dominates Industry Awards in 2024 - StockTitan
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research - Silicon Canals
ICON appoints Barry Balfe as COO - MSN
Bioanalytical Services Market Key Players AnalysisPPD, Inc., - openPR
ICON plc appoints Barry Balfe as new COO By Investing.com - Investing.com Australia
ICON plc Appoints Barry Balfe as Chief Operating Officer - TipRanks
ICON plc appoints Barry Balfe as new COO - Investing.com
ICON Appoints 20-Year Veteran Barry Balfe as Chief Operating Officer to Drive Strategic Growth - StockTitan
Truist Financial Reaffirms Buy Rating for ICON Public (NASDAQ:ICLR) - MarketBeat
ICON's SWOT analysis: CRO giant navigates turbulent market - Investing.com
October 2025 Options Now Available For Icon - Nasdaq
Contract Research Organization Services Market Set to Witness Significant Growth by 2024-2031: IQVIA, LabCorp, - EIN News
ICON's SWOT analysis: cro stock navigates challenges amid industry shifts - Investing.com
Preclinical Assets Market CAGR of 7.5% Size, Share, Trends, Future Prospect By 2024-2031 | Eurofins - EIN News
Biomarker Research Services Market Set to Witness Significant Growth by 2024-2031:Reprocell Corporation, - EIN News
At US$219, Is ICON Public Limited Company (NASDAQ:ICLR) Worth Looking At Closely? - Simply Wall St
ICON Public Limited Company (ICLR) Fell on Reduced Guidance - Insider Monkey
Virtual Clinical Trials Market Key Players AnalysisICON, plc; Parexel International Corporation; IQVIA; Covance. - openPR
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption - sharewise
Top 30 IQVIA Alternatives & Competitors in 2025 - Marketing91
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
ICON (NASDAQ:ICLR) stock performs better than its underlying earnings growth over last five years - Simply Wall St
Should You Retain Your Conviction in Icon Plc (ICLR)? - Yahoo Finance
ICON stock labeled a "Fresh Pick" as Baird bets on recovery at current valuation - Investing.com
Pharmacovigilance and Drug Safety Software Market Skyrockets to $359.30 Million by 2031 Dominated by Tech GiantsArisEurope, ICON plc and Syneos Health | The Insight Partners - GlobeNewswire
Redburn Atlantic Initiates Coverage of ICON Public Limited (ICLR) with Neutral Recommendation - MSN
ICON Public Limited (NASDAQ:ICLR) Shares Sold by Entropy Technologies LP - MarketBeat
ICON Public Limited Company (ICLR): Among 12 High Growth Large Cap Stocks to Buy Now - Yahoo Finance
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):